Tokyo based Heartseed is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure
Founder and CEO Keiichi Fukuda describes the qualities that Heartseed has built into the cardiomyocytes it is developing to make them potent and durable for patients with cardiovascular disease. Six patients have already been dosed in a proof-of-concept clinical trial in Japan.